<DOC>
	<DOCNO>NCT01392807</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetics NKTR-118 patient impaired hepatic function versus subject normal hepatic function .</brief_summary>
	<brief_title>Open-label Study Assess Pharmacokinetics NKTR-118 Patients With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Pathologic Processes</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Males female age 18 year weight least 50 kg BMI 18 40 kg/m2 , inclusive . Negative screen human immunodeficiency virus ( HIV ) For subject normal hepatic function , negative result serum hepatitis B ( HBV ) surface antigen , HCV antibody , HIV Plasma blood product donation within 1 month screen blood donation/blood loss great 500 mL 3 month prior screen . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity Known suspect history drug/chemical abuse within past 2 year judge Investigator . Subjects history surgery gastrointestinal tract . For patient hepatic impairment , fluctuate rapidly deteriorate hepatic function indicate clinical and/or laboratory sign hepatic impairment ( e.g . advanced ascites , infection ascites , fever , active gastrointestinal bleeding ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>volunteer hepatic impairment</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>NKTR-118</keyword>
	<keyword>Child-Pugh scale</keyword>
	<keyword>AUC</keyword>
	<keyword>Cmax</keyword>
	<keyword>tmax</keyword>
	<keyword>t1/2</keyword>
</DOC>